Next-Generation Dual-Target Antibody Extends Life in Advanced Lung Cancer: ASCO 2026

June 1, 2026 | Chicago, IL

A groundbreaking clinical trial presented at the American Society of Clinical Oncology (ASCO) 2026 annual meeting has revealed that ivonescimab, an experimental lung cancer drug developed by China-based Akeso Inc., significantly extends survival in patients with advanced squamous non-small cell lung cancer (NSCLC) compared to a current standard immunotherapy treatment.

The phase III trial, known as HARMONi-6, showed that patients receiving ivonescimab combined with chemotherapy lived a median of 27.9 months compared to 23.7 months for those treated with the established checkpoint inhibitor tislelizumab (brand name Tevimbra) plus chemotherapy. This 4.2-month extension represents a 15% improvement in overall survival and a 34% reduction in the absolute risk of death, marking a major milestone in the treatment of a particularly aggressive form of lung cancer.

Key Findings from the HARMONi-6 Trial

The HARMONi-6 trial is a landmark study involving 532 patients with previously untreated, advanced squamous NSCLC. Participants were randomly assigned in equal numbers to receive either ivonescimab plus chemotherapy or tislelizumab plus chemotherapy.

Conducted across multiple centers in China, the trial represents the first head-to-head Phase III comparison showing the clinical superiority of a novel bispecific antibody regimen over an active, established anti-PD-1 immunotherapy control in a first-line treatment setting.

The survival metrics underscore the consistency of the drug’s performance:

Notably, the survival benefit remained consistent across all prespecified patient subgroups. This included individuals with low or completely absent PD-L1 expression (Tumor Proportion Score, or TPS, less than 1%). Historically, these patients derive far less benefit from standard single-target checkpoint inhibitors.

For the low PD-L1 group, the median survival was “not evaluable” for the ivonescimab arm because more than half of the patients were still alive at the data cutoff, compared to a definitive median of 18.6 months in the tislelizumab control arm.

Understanding the Science: A First-in-Class Dual-Target Approach

Ivonescimab represents an innovative class of oncology therapeutics known as a bispecific antibody. Traditional immunotherapies, like standard PD-1 inhibitors, act like single-key locks. They unmask cancer cells so the body’s native immune system can recognize and destroy them.

However, tumors often bypass this defense by shifting to alternative survival mechanisms, such as stimulating angiogenesis—the growth of new blood vessels that feed the tumor.

Ivonescimab utilizes a engineered tetravalent structure to target two pathways at once:

• PD-1 Blockade: Reactivates the immune system’s T-cells to aggressively attack the cancer.

• VEGF Inhibition: Blocks Vascular Endothelial Growth Factor (VEGF), which starves the tumor’s blood supply, normalizes chaotic tumor blood vessels, and allows immune cells to penetrate deeper into the tumor core.

Outside of China, the drug is being co-developed and commercialized by Florida-based Summit Therapeutics, which has partnered with Akeso to spearhead international development and future Western regulatory submissions.

Expert Commentary: Cautious Optimism from the Oncology Community

Dr. Shun Lu, the principal investigator of the trial from the Shanghai Chest Hospital at Shanghai Jiao Tong University School of Medicine, presented the findings during ASCO’s high-profile plenary session.

“HARMONi-6 is the first global Phase III study in lung cancer to show statistically significant improvements in both overall survival and progression-free survival compared with an active PD-1 inhibitor plus chemotherapy control,” Dr. Lu stated. “These strong head-to-head data redefine the gold standard for first-line treatment in this setting.”

Independent oncology experts not involved in the trial expressed measured enthusiasm. Historically, squamous lung cancer has been exceptionally difficult to treat, often carrying a worse prognosis than non-squamous variations.

The American Cancer Society estimates that approximately 229,410 new cases of lung cancer will be diagnosed in the United States in 2026, resulting in roughly 124,990 deaths. Squamous cell carcinoma accounts for roughly 29% to 30% of those cases globally, showing a strong correlation with tobacco smoke exposure.

Safety Profile and Treatment Side Effects

While the efficacy data generated considerable excitement, the combination regimen demands careful clinical management. Severe adverse events—classified as Grade 3 or higher treatment-related side effects—occurred more frequently in the ivonescimab group (69.2%) compared to the tislelizumab control group (58.9%).

Commonly documented side effects associated with this dual-therapy approach include:

• Fatigue and profound lethargy

• Nausea and decreased appetite

• Immune-related inflammation affecting the lungs (pneumonitis), liver, or endocrine organs

• Mild to moderate hemorrhage (bleeding) or hypertension, which are well-known side effects linked directly to anti-VEGF vascular therapies.

Despite the higher numerical rate of severe side effects, investigators noted that the rates of adverse events actually leading to permanent drug discontinuation or treatment-related death were statistically similar between both arms, suggesting that experienced clinical oncologists can safely manage the toxicity profile.

Important Limitations and Considerations

Medical experts urge patients and clinicians to view the data through a balanced lens, noting several prominent trial limitations:

• Geographic Homogeneity: The entire HARMONi-6 trial was conducted within mainland China. Global regulatory authorities, including the U.S. Food and Drug Administration (FDA), typically require clinical data reflecting more racially and ethnically diverse populations to ensure that variations in metabolism, genetics, and baseline standard of care do not alter the drug’s safety or efficacy profile.

• Lack of 5-Year Data: With a median study follow-up of 21.4 months, true long-term curative metrics remain unknown. Real-world 5-year survival rates for advanced squamous NSCLC on standard immunotherapies hover between 18% and 22%.

• Regulatory Status: Ivonescimab is approved for specific lung cancer indications in China and features on its National Reimbursement Drug List. However, it is not yet approved by the FDA or the European Medicines Agency (EMA), meaning it remains unavailable to Western patients outside of active clinical trials.

What This Means for Patients

For families currently navigating a diagnosis of advanced squamous non-small cell lung cancer, these data offer clear, scientifically backed hope. A median survival extension of over four months is a substantial window of time in advanced oncology.

However, patients must remember that clinical trial averages do not guarantee individual outcomes. Real-world survival varies widely based on personal performance status, underlying organ health, and exact genetic tumor profiles.

Currently, Summit Therapeutics is recruiting Western patients for the global HARMONi-3 trial, which directly compares ivonescimab against pembrolizumab (Keytruda)—the current backbone of U.S. lung cancer care. Patients interested in accessing this therapy prior to FDA approval should consult their oncology team regarding eligibility for these ongoing international clinical trials.

Reference Section

• https://www.reuters.com/business/healthcare-pharmaceuticals/akeso-lung-cancer-drug-helps-patients-live-15-longer-than-immunotherapy-china-2026-05-31/

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.